glp 1 agonist shortage GLP-1 trends 2025: real-world data, patient outcomes & future therapies π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Description
PMCID: PMC12075970
There was a non-significant decreased risk of CRC when compared with alpha-glucosidase or DPP-4i
In some cases, patients may take microdoses as part of a titration process, slowly increasing as tolerated
In comparison, when looking at GLP-1s, research suggests that people tend to put the weight back when they stop taking their medications, with just 39% of the weight lost sustained at one year after medical treatment has been stopped
Chen YC, Jandeleit-Dahm K, Peter K
Philip Pape: 8:24 Anyway, back to the topic how can we use this information
